PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF VONOPRAZAN 20 MG VERSUS LANSOPRAZOLE 30 MG IN THE TREATMENT OF ENDOSCOPICALLY CONFIRMED DUODENAL ULCERS IN ASIAN SUBJECTS WITH OR WITHOUT HELICOBACTER PYLORI INFECTION

Xiaohua Hou  ¹     Fandong Meng  ²     Jiangbin Wang  ³     Weihong Sha  ⁴     Cheng Tang Chiu  ⁵     Woo Chul Chung  ⁶     Liqun Gu  ⁷     Kentarou Kudou  ⁸     Chui Fung Chong  ⁹     Shutian Zhang  ^9    
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
² Beijing Friendship Hospital, Capital Medical University, Beijing, China
³ China-Japan Union Hospital, Jilin University, Changchun, China
⁴ Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangdong Geriatrics Institute, Guangdong, China
⁵ Linkou Medical Center, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan, Taiwan
⁶ St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (Republic of)
⁷ Takeda Development Center Asia, Shanghai, China
⁸ Takeda Pharmaceutical Company, Osaka, Japan
⁹ Takeda Development Center Asia, Singapore, Singapore

Session
H. pylori (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)